Scotiabank upgraded its rating of Legend Biotech (NASDAQ:LEGN) to sector outperform, citing valuation and commercial expansion of its drug Carvykti, which was co-developed with Johnson & Johnson (JNJ)...
Source LinkScotiabank upgraded its rating of Legend Biotech (NASDAQ:LEGN) to sector outperform, citing valuation and commercial expansion of its drug Carvykti, which was co-developed with Johnson & Johnson (JNJ)...
Source Link
Comments